Manufacturer
INTAS PHARM LTD
Contents
CISPLATIN
Indication
Metastatic ovarian cancer, Metastatic testicular tumours, Advanced bladder cancer
Instruction
Administer via IV by Healthcare Personnel.
Drug interaction
Synergistic with 5-fluorouracil and etoposide. Efficacy increased and toxicity reduced when combined with radioprotecting agent WR 2721. At doses ≤100 mg, cisplatin is an ideal drug to combine with other cytotoxic drugs; unlike other antineoplastic drugs, it causes little myelosuppression.
Potentially Fatal: Potentiates nephrotoxicity with aminoglycosides. Increased toxicity when combined with other cytotoxic drugs.
Malaysia
